ARMP (STOCKS)
Armata Pharmaceuticals, Inc. Common Stock
$11.930000
+0.810000 (+7.28%)
Prev close: $11.120000
Company Information
- Exchange
- XASE
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Deborah L. Birx
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $428.24M
- Employees
- 75
- P/E (TTM)
- -2.32
- P/B (TTM)
- -1.85
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
2
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-3.27 | $-0.29 | -2.9844 | -1,044.96% |
|
Sep 2025 (Q3)
|
$-0.74 | $-0.43 | -0.3116 | -72.74% |
|
Jun 2025 (Q2)
|
$-0.45 | $-0.40 | -0.0522 | -13.12% |
|
Mar 2025 (Q1)
|
$-0.20 | $-0.39 | +0.1876 | +48.40% |
Financial Statements
| Revenues | $4.90M |
| Benefits Costs and Expenses | $178.70M |
| Costs And Expenses | $41.54M |
| Operating Expenses | $41.54M |
| Operating Income/Loss | -$36.63M |
| Income/Loss From Continuing Operations After Tax | -$173.80M |
| Income/Loss From Continuing Operations Before Tax | -$173.80M |
| Net Income/Loss | -$173.80M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$173.80M |
| Net Income/Loss Available To Common Stockholders, Basic | -$173.80M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$4.80 |
| Diluted Earnings Per Share | -$4.80 |
| Basic Average Shares | 36,239,253 |
| Diluted Average Shares | 36,239,253 |
| Assets | $76.88M |
| Current Assets | $10.67M |
| Noncurrent Assets | $66.21M |
| Fixed Assets | $12.19M |
| Intangible Assets | $10.26M |
| Other Non-current Assets | $43.76M |
| Liabilities | $295.48M |
| Current Liabilities | $8.95M |
| Accounts Payable | $921.00K |
| Other Current Liabilities | $8.03M |
| Noncurrent Liabilities | $286.53M |
| Equity | -$218.60M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | -$218.60M |
| Liabilities And Equity | $76.88M |
| Net Cash Flow From Operating Activities | -$25.76M |
| Net Cash Flow From Operating Activities, Continuing | -$25.76M |
| Net Cash Flow From Investing Activities | -$542.00K |
| Net Cash Flow From Investing Activities, Continuing | -$542.00K |
| Net Cash Flow From Financing Activities | $25.61M |
| Net Cash Flow From Financing Activities, Continuing | $25.61M |
| Net Cash Flow | -$693.00K |
| Net Cash Flow, Continuing | -$693.00K |
| Comprehensive Income/Loss | -$173.80M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$173.80M |
| Other Comprehensive Income/Loss | $0.00 |